Intracellular Bacteria and Protozoa - Intracellular Delivery: Fundamentals and Applications - page 810

pharmacokinetics of a liposomal ciprofloxacin formulation. Antimicrob Agents Chemother
42(1): 45-52
Weinberger M, Keller N (2005) Recent trends in the epidemiology of non-typhoid Salmonella and
antimicrobial resistance: the Israeli experience and worldwide review. Curr Opin Infect Dis
18(6): 513-521
Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB (2000) The
design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid
molecular transporters. Proc Natl Acad Sci USA 97: 13003-13008
Werner-Meier R, Entzeroth R (1997) Diffusion of microinjected markers across the parasito-
phorous vacuole membrane in cells infected with Eimeria nieschulzi (Coccidia, Apicomplexa).
Parasitol Res 83: 611-613
Whittum-Hudson JA, Hudson AP (2005) Human chlamydial infections: persistence, prevalence
and outlook for the future. Nat Sci Soc 13: 371-382
Whitty CJM, Sanderson F (1999) New therapies and changing patterns of treatment for malaria.
Curr Opin Infect Dis 12: 579-584
Wijagkanalan W, Kawakami S, Takenaga M, Igarashi R, Yamashita F, Hashida M (2008) Efficient
targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes
in rats. J Control Release 125: 121-130
Wiström J, Jertborn M, Ekwall E, Norlin K, Söderquist B, Strömberg A, Lundholm R, Hogevik
H, Lagergren L, Englund G, et al. (1992) Empiric treatment of acute diarrheal disease with
norfloxacin. A randomized, placebo-controlled study. Swedish Study Group. Ann Intern Med
117(3): 202-208
Wong JP, Yang H, Blasetti KL, Schnell G, Conley J, Schofield LN (2003) Liposome delivery of
ciprofloxacin against intracellular Francisella tularensis infection. J Control Release 92:
265- 273
World Health Organization (WHO) (1993) declares tuberculosis a global emergency. Soc. Prevent.
Med. 38: 251-252
World Health Organization (WHO) (2003) Treatment of tuberculosis: guidelines for national
programmes 3rd Geneva
World Health Organization (WHO) (2006) Guidelines for the Treatment of Malaria http://
www.whqlibdoc.who.int/publications /2006/9241546948_eng.pdf , accessed on 20th March
2009
World Health Organization (WHO) (2008) Global tuberculosis control: surveillance, planning,
financing: report http://www.who.int/tb/publications/global_report/2008/pdf/fullreport.pdf .
Accessed February 2008
Wortmann G, Zapor M, Ressner R, Fraser S, Hartzell J, Pierson J, Weintrob A, Magill A (2010)
Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg
83(5): 1028-1033
Yardley V, Croft SL (1997) Activity of liposomal amphotericin B against experimental cutaneous
leishmaniasis. Antimicrob Agents Chemother 41: 752-756
Yardley V, Croft SL (1999) In vitro and in vivo activity of amphotericin B-lipid formulations
against experimental Trypanosoma cruzi infections. Am J Trop Med Hyg 61: 193-197
Yardley V, Croft SL (2000) A comparison of the activities of three amphotericin B lipid formula-
tions against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents 13:
243-248
Yoshida A, Matumoto M, Hshizume H, Oba Y, Tomishige T, Inagawa H, Kohchi C, Hino M, Ito
F, Tomoda K, Nakajima T, Makino K, Terada H, Hori H, Soma G (2006) Selective delivery of
rifampicin incorporated into poly (DL-lactic-co-glycolic) acid microspheres after phagocytotic
uptake by alveolar macrophages, and the killing effect against intracellular Mycobacterium
bovis Calmettee Guérin. Microbes Infect 8: 2484-2491
Yoshihara E, Tachaban H, Nakae T (1987) Trypanocidal activity of the stearylamine - bearing
liposome. Life Sci 40: 2153-2159
Yuji O (2010) Chlamydial Pneumonias. http://emedicine.medscape.com/article/297351-overview .